News Search Results
Jul 31, 2025, 07:30 ET Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Jul 31, 2025, 07:05 ET REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jul 31, 2025, 07:00 ET Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board
Mass., July 31, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the appointment
More news about: Marengo Therapeutics
Jul 31, 2025, 06:45 ET Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 31, 2025, 06:00 ET ESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilities
at the heart of everything it does. About Regis Technologies Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization
More news about: ESTEVE
Jul 31, 2025, 04:24 ET ESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilities
at the heart of everything it does. About Regis Technologies Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization
More news about: ESTEVE
Jul 31, 2025, 01:23 ET Nscale, Aker and OpenAI to establish Stargate Norway: a 100,000 NVIDIA GPU AI Gigafactory powered by renewable energy in Northern Norway
majority-owned by TRG, a company controlled by Aker's Chairman, Kjell Inge Røkke. Aker's portfolio spans energy, industrial software, renewables, marine biotechnology, and seafood. It is the largest shareholder in several listed and privately held companies, combining deep industrial expertise with financial strength
More news about: Aker ASA
Jul 30, 2025, 22:06 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Plus is a life sciences software and consulting company that provides advanced biosimulation tools and consulting services to pharmaceutical and biotechnology companies worldwide. THE ALLEGED WRONGDOING: On July 14, 2025, Simulations Plus reported
More news about: Edelson Lechtzin LLP
Jul 30, 2025, 13:58 ET ARCHIMED Acquires a Majority Stake in Arkstone, Forging a Powerful Partnership to Accelerate Global Healthcare Innovation And Dominate the Emerging AI-Driven Clinical Decision Support Market
Arkstone, an innovative biotechnology company democratizing infectious disease expertise and fighting antimicrobial resistance, has been acquired by global healthcare private equity firm ARCHIMED, which now holds a majority stake. BOCA
More news about: Arkstone
Jul 30, 2025, 11:22 ET Robbins LLP Reminds CAPR Investors with Large Losses of the Class Action Lawsuit on Behalf of Capricor Therapeutics, Inc. Shareholders
securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating
More news about: Robbins LLP
Jul 30, 2025, 11:00 ET Espervita's EVT0185 Shows Dramatic Tumor Reduction and Immune Activation in Preclinical MASH-Driven Hepatocellular Carcinoma
Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in
More news about: Espervita Therapeutics, Inc.
Jul 30, 2025, 11:00 ET Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
LinkedIn. 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jul 30, 2025, 10:30 ET Biosimilars Market is Estimated to Reach USD 88.9 Billion by 2032 | SkyQuest Technology Consulting
https://www.skyquestt.com/report/cancer-biological-therapy-marketBiotechnology Market - https://www.skyquestt.com/report/biotechnology-marketAbout SkyQuest Technology Consulting Group
More news about: SkyQuest Technology
Jul 30, 2025, 10:15 ET With 5.9%, Ballistic Protection Market to reach USD 23.69 billion by 2031 | Experiences Growth in Business Aviation Sector | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Jul 30, 2025, 10:01 ET C-Parts Market to reach USD 212.79 billion by 2031, due to an Increase in Orders and Deliveries of Aircraft and Automobiles Worldwide | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Jul 30, 2025, 09:01 ET Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy
bioeconomy fundamental science. We hope this transformative public-private partnership will catalyze innovation and advance our global leadership in biotechnology. Ginkgo Automation capabilities can now be deployed at your site. Find out more about our RACs and Catalyst automation software
More news about: Ginkgo Bioworks
Jul 30, 2025, 09:00 ET New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
LinkedIn. 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jul 30, 2025, 08:30 ET AI in Clinical Trials: Early Use Cases and Innovations, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare, and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jul 30, 2025, 08:30 ET Dose Escalation: Optimizing Cohort Management in Early-Phase Development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jul 30, 2025, 08:30 ET How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jul 30, 2025, 08:15 ET Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice
More news about: Anixa Biosciences, Inc.
Jul 30, 2025, 08:07 ET Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
LinkedIn.About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jul 30, 2025, 08:01 ET Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 30, 2025, 06:10 ET REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc.
between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
More news about: Robbins LLP
Jul 30, 2025, 00:00 ET Securities Class Action Filings Remain Steady While Size of Filings Increased Substantially in First Half of 2025
The number of filings in the Consumer Non-Cyclical sector increased by 31% in 2025 H1 relative to 2024 H2, largely driven by a surge in Biotechnology and Pharmaceutical filings.Mega filings accounted for the vast majority of total MDL and total DDL (91% and 83%, respectively), significantly
More news about: Cornerstone Research